Pharmaxis (NASDAQ:PXSL) – Phase II Trial of Bronchitol Successful

August 12, 2008
On 8/11/2008, Pharmaxis (NASDAQ:PXSL) declared success in its Phase II trial of DPM-CF-202, a unique agent that has shown efficacy in the treatment of patients with cystic fibrosis.  Cystic Fibrosis is a genetic disorder that commonly leads to decrease in lung funtion.  At the end of two weeks of treatment with DPM-CF-202 (Bronchitol), cystic fibrosis patient displayed an increase in lung function.  In the late 90’s It was estimated that the cost of patients with cystic fibrosis was $314 million per year in 1996 dollars. Twelve years later there has been no significant breakthrough and the cost of Cystic Fibrosis patients is most likely close to half a billion dollars a year.  If Bronchitol passes through it’s phase three clinical trials and gets placed on Pharmaceutical Markets Worldwide it may lead to hundreds of millions of dollars in revenue for Pharmaxis.  An increase in revenue may lead to an increase in stock price for Pharmaxis.